NUDT5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5803152	0.68	3/20
SCHEMBL200349	0.62	3/20
SCHEMBL4478592	0.55	3/20
SCHEMBL130529	1.00	2/20
Ibrutinib (SCHEMBL201641)	1.00	2/20
Ibrutinib (SCHEMBL201642)	1.00	2/20
Ibrutinib (SCHEMBL201859)	1.00	2/20
Ibrutinib (SCHEMBL2244865)	1.00	2/20
Ibrutinib (SCHEMBL2244870)	1.00	2/20
SCHEMBL5804616	0.93	2/20
SCHEMBL200391	0.91	2/20
SCHEMBL200392	0.91	2/20
SCHEMBL201548	0.91	2/20
SCHEMBL1613606	0.88	2/20
SCHEMBL6430440	0.87	2/20
SCHEMBL6430567	0.85	2/20
SCHEMBL6430568	0.85	2/20
SCHEMBL1614256	0.83	2/20
SCHEMBL202187	0.81	2/20
SCHEMBL1614258	0.81	2/20

Clinical trials — most relevant to NUDT5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Hypophosphatemic Rickets in Norway	nan	UNKNOWN
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles	nan	ACTIVE_NOT_RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Studying Phosphorus Metabolism	nan	COMPLETED
Study of Constitutional Platelet Disease	nan	UNKNOWN
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)	nan	COMPLETED
Gene Analysis of Parkinson's Disease	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Phenotype/Genotype Correlations in Neuromuscular Disorders	nan	COMPLETED
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Genetic Investigation of Cancer Predisposition	nan	NOT_YET_RECRUITING
Germline Mutations in Pancreatic Adenocarcinoma	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Epidemiology of Gout in French Polynesia	nan	COMPLETED
Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NUDT5 binder may also engage these)

Protein	Name	Similarity
Q5RCY2	—	1.000	Q5RCY2 →
Q6AY63	—	0.993	Q6AY63 →
Q9JKX6	—	0.990	Q9JKX6 →
Q9P791	—	0.990	Q9P791 →
Q01976	—	0.981	Q01976 →
O61902	—	0.978	O61902 →
P13420	—	0.974	P13420 →
O42641	—	0.970	O42641 →
Q8VYX1	—	0.970	Q8VYX1 →
P0C024	—	0.969	P0C024 →
A0A1D6NER6	—	0.968	A0A1D6NER6 →
Q5XIG0	—	0.968	Q5XIG0 →
P93648	—	0.968	P93648 →
A2YQ56	—	0.968	A2YQ56 →
P11035	—	0.968	P11035 →
Q9DCN1	—	0.968	Q9DCN1 →
Q5RD76	—	0.967	Q5RD76 →
P11832	—	0.967	P11832 →
Q58H57	—	0.967	Q58H57 →
Q9C6Z2	—	0.967	Q9C6Z2 →
Q944H0	—	0.967	Q944H0 →
Q09509	—	0.967	Q09509 →
Q8K370	—	0.967	Q8K370 →
O82399	—	0.967	O82399 →
P56380	—	0.967	P56380 →
Q8LET2	—	0.967	Q8LET2 →
O88428	—	0.967	O88428 →
Q99P30	—	0.967	Q99P30 →
P00927	—	0.967	P00927 →
P16638	—	0.966	P16638 →